RXi Pharmaceuticals Corp. (RXII) Announces Product Candidate to Reduce Surgical Scarring
RXi Pharmaceuticals Corp., a leader in RNAi-based therapeutic discovery and development, recently announced RXI-109 as its first RNAi therapeutic product candidate to advance into development. RXI–109 is a self-delivering RNAi compound designed to reduce dermal scarring in planned surgeries. The company notes scar prevention and reduction as an unmet therapeutic medical need with a potential market of up to $4 billion a year. Anti-scarring, or anti-fibrotic treatments, are being developed to not only address the cosmetic issues of scarring, but also to treat other medical conditions where excess scarring and/or fibrosis may occur, and might possibly be painful. “Dermal anti-scarring…